HISTORY

Lux Biosciences was founded in 2006 with a series A financing and the in-licensing of worldwide exclusive rights in all ophthalmic indications to intellectual property covering LUVENIQ™ (LX211/voclosporin capsule) from Isotechnika Inc. Based on regulatory interactions with the United States Food and Drug Administration and European health authorities, the company was able to progress its development programs for LUVENIQ™ into Phase 3 clinical trials at the beginning of 2007. Three pivotal studies were initiated enrolling over 500 patients worldwide. As of the middle of 2009, all of the pivotal studies were completed. Through collaboration with the University of Missouri, Kansas City, LX214, a proprietary topical product containing voclosporin for dry eye has been formulated and has completed Phase 1 clinical development. The company has also expanded its portfolio with an exclusive license to a proprietary bio-erodible polymer technology originally invented at Rutgers University. Animal studies for LX212, a bio-erodable ocular polymer implant containing voclosporin, are ongoing.